Results 21 to 30 of about 12,566,431 (163)

Blood coagulation parameters in fallow deer (Dama dama)

Veterinární Medicína, 2011
There are frequent reports from around the world of wild animals being poisoned with anticoagulants. Granulated baits can result in primary or secondary poisoning of non-target animals.
Z. Siroka, B. Krocilova, J. Pikula, H. Bandouchova, L. Peckova, F. Vitula   +5 more
doaj   +1 more source

The Liver That Cured Christmas: Case Report of Orthotopic Liver Transplant in a Patient with Hemophilia B

Case Reports in Transplantation, 2020
Herein, we discuss a case of a 39-year-old male with hemophilia B, who developed end-stage liver disease secondary to nonalcoholic steatohepatitis, that underwent orthotopic liver transplantation (OLT) as a curative means for his liver disease and ...
Jesse E. Harris, Jonathan L. Balk, Constance M. Mobley, Kirk Heyne   +3 more
doaj   +1 more source

“Prevalence of Inhibitors in Hemophilia Patients and its Clinical Implications”: A Study of 276 Patients in Western India

Global Journal of Transfusion Medicine, 2019
Introduction: Hemophilia is an X-linked congenital bleeding disorder caused by a deficiency of coagulation factor VIII (FVIII) in hemophilia A (HA) or factor IX (FIX) in hemophilia B (HB).
Sangita Darshan Shah, Tarak R Patel, Nidhi M Bhatnagar, Maitrey D Gajjar, Mamta Chintan Shah, Sujata Tripathi   +5 more
doaj   +1 more source

A computer‐based model to assess costs associated with the use of factor VIII and factor IX one‐stage and chromogenic activity assays

Journal of Thrombosis and Haemostasis, 2016
Essentials Chromogenic factor VIII and factor IX assays have not been widely adopted partly due to perceived cost. Chromogenic assays may be needed for monitoring therapy with some extended half‐life concentrates.
S. Kitchen, J. Blakemore, K. Friedman, D. Hart, R. Ko, R. Ko, D. Perry, S. Platton, D. Tan-Castillo, G. Young, G. Young, R. Luddington   +11 more
semanticscholar   +1 more source

Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

Haemophilia, 2015
rIX‐FP is a coagulation factor IX (recombinant), albumin fusion protein with more than fivefold half‐life prolongation over other standard factor IX (FIX) products available on the market.
U. Martinowitz, T. Lissitchkov, A. Lubetsky, G. Jotov, Tami Barazani-Brutman, Christine Voigt, Iris Jacobs, T. Wuerfel, Elena Santagostino   +8 more
semanticscholar   +1 more source

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.

Blood, 2014
This multinational, randomized, single-blind trial investigated the safety and efficacy of nonacog beta pegol, a recombinant glycoPEGylated factor IX (FIX) with extended half-life, in 74 previously treated patients with hemophilia B (FIX activity ≤2 IU ...
P. Collins, G. Young, K. Knobe, F. A. Karim, P. Angchaisuksiri, C. Banner, T. Gürsel, J. Mahlangu, T. Matsushita, E. Mauser-Bunschoten, J. Oldenburg, C. Walsh, C. Négrier   +12 more
semanticscholar   +1 more source

Efficacy of a high-purity factor IX concentrate in hemophilia B patients undergoing surgery [PDF]

Revista Brasileira de Hematologia e Hemoterapia, 2002
A plasma derived, high purity, solvent-detergent treated and subsequently nanofiltered factor IX concentrate (BEMOFIL) was evaluated in 19 hemophilia B patients, including four with severe, thirteen with mild or moderate type of disease and two ...
Vesa Rasi, Freja Ebeling
doaj   +1 more source

Beware of Reversal of an Anticoagulated Patient with Factor IX in the Emergency Department: Case Report of a Medical-Legal Misadventure

Clinical Practice and Cases in Emergency Medicine, 2020
In this article we present a case of a patient who received reversal of anticoagulation therapy with factor IX in violation of hospital guidelines. As a direct result, myocardial infarction and ischemic stroke occurred, leaving the patient neurologically
Steven Gannon, David Bell, Kenneth Jackmiczyk, Gregory Moore   +3 more
doaj   +1 more source

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

New England Journal of Medicine, 2013
BACKGROUND Prophylactic factor replacement in patients with hemophilia B improves outcomes but requires frequent injections. A recombinant factor IX Fc fusion protein (rFIXFc) with a prolonged half-life was developed to reduce the frequency of injections
J. Powell, K. Pasi, M. Ragni, M. Ozelo, L. Valentino, J. Mahlangu, M. Med, N. Josephson, D. Perry, M. Manco‐Johnson, Shashikant Apte, R. Baker, G. C. Chan, N. Novitzky, R. Wong, S. Krassova, G. Allen, Haiyan Jiang, A. Innes, Shuanglian Li, L. Cristiano, J. Goyal, J. Sommer, J. Dumont, Karen Nugent, G. Vigliani, Aoife Brennan, A. Luk, G. Pierce   +28 more
semanticscholar   +1 more source

Clinical profile and demographic characteristics of moderate and severe hemophilia patients in a tertiary care hospital of Bangladesh

Orphanet Journal of Rare Diseases, 2022
Background Hemophilia is one of the commonest inherited bleeding disorders which may lead to chronic bleeding tendencies and life-long disabilities if not properly managed.
Mohammed Nadimul Islam, Akhil Ranjon Biswas, Humayra Nazneen, Nobendu Chowdhury, Mahbubul Alam, Jayanta Banik, Md. Kamrul Hassan, Abdullah Az Zubayer Khan, Najmul Karim, Mohammad Jahid Hasan, Md. Abdullah Saeed Khan   +10 more
doaj   +1 more source